Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1962 1
1965 1
1967 3
1968 1
1969 2
1970 15
1971 9
1972 4
1973 8
1974 9
1975 8
1976 11
1977 10
1978 9
1979 8
1980 12
1981 16
1982 17
1983 7
1984 11
1985 13
1986 17
1987 14
1988 16
1989 10
1990 14
1991 16
1992 18
1993 21
1994 37
1995 28
1996 25
1997 27
1998 17
1999 30
2000 25
2001 23
2002 30
2003 22
2004 34
2005 30
2006 24
2007 31
2008 25
2009 25
2010 14
2011 26
2012 24
2013 45
2014 42
2015 43
2016 33
2017 48
2018 40
2019 25
2020 32
2021 29
2022 30
2023 34
2024 40
2025 51
2026 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,232 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Taylor HS, et al. Among authors: archer df. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19. N Engl J Med. 2017. PMID: 28525302 Free article. Clinical Trial.
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Among authors: archer d. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.
White Matter Abnormalities and Cognition in Aging and Alzheimer Disease.
Peter C, Sathe A, Shashikumar N, Pechman KR, Workmeister AW, Jackson TB, Huo Y, Mukherjee S, Mez J, Dumitrescu LC, Gifford KA, Bolton CJ, Gaynor LS, Risacher SL, Beason-Held LL, An Y, Arfanakis K, Erus G, Davatzikos C, Tosun-Turgut D, Habes M, Wang D, Toga AW, Thompson PM, Zhang P, Schilling KG, Albert M, Kukull W, Biber SA, Landman BA, Bendlin BB, Johnson SC, Schneider J, Barnes LL, Bennett DA, Jefferson AL, Resnick SM, Saykin AJ, Crane PK, Cuccaro ML, Hohman TJ, Archer DB; and the Alzheimer’s Disease Sequencing Project Phenotype Harmonization Consortium (ADSP-PHC) Analyst Team; Zaras D, Yang Y, Durant A, Kanakaraj P, Kim ME, Gao C, Newlin NR, Ramadass K, Khairi NM, Li Z, Yao T, Choi SE, Klinedinst B, Lee ML, Scollard P, Trittschuh EH, Sanders EA. Peter C, et al. Among authors: archer db. JAMA Neurol. 2025 Aug;82(8):825-836. doi: 10.1001/jamaneurol.2025.1601. Epub 2025 Jun 9. JAMA Neurol. 2025. PMID: 40513084 Free PMC article.
Genetic modifiers of APOE-ε4-associated cognitive decline.
Contreras AG, Walters S, Eissman JM, Archer DB, Regelson AN, Durant A, Clifton M, Mukherjee S, Lee ML, Choi SE, Scollard P, Trittschuh EH, Mez J, Bush WS, Kunkle BW, Cruchaga C, Naj AC, Gifford KA, Bilgel M, Kuzma AB; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer’s Disease Genetics Consortium (ADGC); Alzheimer’s Disease Sequencing Project (ADSP); Cuccaro ML, Pericak-Vance MA, Farrer LA, Wang LS, Schellenberg GD, Haines JL, Jefferson AL, Kukull WA, Keene CD, Saykin AJ, Thompson PM, Martin ER, Albert MS, Johnson SC, Engelman CD, Ferrucci L, Bennett DA, Barnes LL, Schneider JA, Sperling RA, Resnick SM, Crane PK, Dumitrescu L, Hohman TJ. Contreras AG, et al. Among authors: archer db. Nat Commun. 2026 Feb 20;17(1):2982. doi: 10.1038/s41467-026-68933-z. Nat Commun. 2026. PMID: 41720779 Free PMC article.
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials.
Chen MJ, Jensen JT, Kaunitz AM, Achilles SL, Zatik J, Weyers S, Piltonen T, Suturina L, Apolikhina I, Bouchard C, Archer DF, Jost M, Foidart JM, Creinin M. Chen MJ, et al. Among authors: archer df. Contraception. 2022 Dec;116:44-50. doi: 10.1016/j.contraception.2022.10.004. Epub 2022 Oct 17. Contraception. 2022. PMID: 36257374 Free article. Clinical Trial.
1,232 results